Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nalpha-(2-Naphthylsulfonylglycyl)-3-Amidino-D,L-Phenylalanine-Isopropylester is a synthetic small molecule belonging to the class of serine protease inhibitors. It is structurally characterized as a peptide derivative and has been studied primarily as an experimental compound, not approved for clinical use. The compound acts by binding to the active site of serine proteases such as trypsin and thrombin, inhibiting their enzymatic activity. Structural studies have shown that it fits into the specificity pocket of these enzymes, with its amidinophenylalanine moiety engaging key residues in the active site[1][4][5]. Its primary research application has been in structural biology and enzymology for understanding protease-inhibitor interactions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Nalpha-(2-Naphthylsulfonylglycyl)-3-Amidino-D,L-Phenylalanine-Isopropylester.